A method to predict the metabolic effects of changes in insulin treatment in subgroups of a large population based patient cohort

European Journal of Epidemiology

Volumn 22, Issue 3, 2007, Pages 151-157

  Österbrand, Marcus ^a   Fahlén, Martin ^b   Odén, Anders ^c   Eliasson, Björn ^d  

^a UDDEVALLA HOSPITAL   (Sweden)

^b Kungalv Hospital   (Sweden)

^c CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Diabetes mellitus; Glargine; HbA1c; Insulin; NPH; Prediction; Regression to the mean

Indexed keywords

GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; SULFONYLUREA;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CIGARETTE SMOKING; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFECT; DRUG SUBSTITUTION; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; POPULATION RESEARCH; SEX DIFFERENCE;

BODY MASS INDEX; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, ISOPHANE; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEX FACTORS;

EID: 33947595905     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-007-9107-4     Document Type: Article

References (30)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
3. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review. JAMA 2003; 289: 2254-2264.
4. Reddy SS. Health outcomes in type 2 diabetes. Int J Clin Pract Suppl 2000; 113: 46-53.
5. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23: 644-649.
6. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A , Cordoni C, Costa E, Brunetti P, Bolli GB. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148.
7. Ratner R, Hirsch I, Neifing J, Garg S, Mecca T, Wilson C, Ratner R. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin glargine in Type 1 Diabetes. Diabetes Care 2000; 23: 639-643.
8. Rosenstock J, Schwartz S, Clark C, Park G, Donley D, Edwards M. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001; 24: 631-636.
9. Porcellati F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Scionti L, Perriello G, Bolli GB. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med 2004; 21: 1213-1220.
10. Stroup J, Kane MP, Busch RS, Bakst G, Hamilton RA. The utility of insulin glargine in the treatment of diabetes mellitus. Pharmacotherapy 2004; 24: 736-742.
11. Garg SK, Gottlieb PA, Hisatomi ME, D'Souza A, Walker AJ, Izuora KE, Chase HP. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract 2004; 66: 49-56.
12. Riddle M, Rosenstock J, Gerich J. The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
13. Massi Benedetti M, Humburg E, Dressler A, Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003; 35: 189-196.
14. Fritsche A, Schweitzer M, Haring H. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003; 138: 952-959.
15. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000; 23: 1130-1136.
16. Chatterjee S, Jarvis-Kay J, Rengarajan T, Lawrence IG, McNally PG, Davies MJ. Glargine versus NPH insulin: Efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes-The glargine and aspart study (GLASS) A randomised cross-over study. 2006 Nov 30; [Epub ahead of print].
17. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, Vahatalo M, Virtamo H, Nikkila K, Tulokas T, Hulme S, Hardy K, McNulty S, Hanninen J, Levanen H, Lahdenpera S, Lehtonen R, Ryysy L. Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study. Diabetologia 2006; 49(3): 442-451.
18. Fulcher GR, Gilbert RE, Yue DK. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J 2005; 35(9): 536-542.
19. Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A. European Insulin Glargine Study Group. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes Metab Res Rev 2005; 21(6): 545-553.
20. Fahlen M, Eliasson B, Oden A. Optimization of basal insulin delivery in Type 1 diabetes: a retrospective study on the use of continuous subcutaneous insulin infusion and insulin glargine. Diabet Med 2005; 22: 382-386.
21. Oden A, Fahlen M. Oral anticoagulation and risk of death: A medical record linkage study. BMJ 2002; 325: 1073-1075.
22. Hoelzel W, Weykamp C, Jeppsson JO, Miedema K, Barr JR, Goodall I, Hoshino T, John WG, Kobold U, Little R, Mosca A, Mauri P, Paroni R, Susanto F, Takei I, Thienpont L, Umemoto M, Wiedmeyer HM. IFCC Working Group on HbA1c Standardization. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 2004; 50: 166-174.
23. Signorello LB, McLaughlin JK, Lipworth L, Friis S, Sorensen HT, Blot WJ. Confounding by indication in epidemiologic studies of commonly used analgesics. Am J Ther 2002; 9(3): 199-205.
24. The diabetes control and complications trial research group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44: 968-983.
25. Chaturvedi N, Sjoelie A-K, Porta M, Aldington S, Fuller J, Songini M, Kohner E. Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. The Eurodiab prospective complications study. Diabetes Care 2001; 24(nr 2): 284-289.
26. Stratton I, Adler A, Neil Matthews AD, Manley S, Cull C, Hadden D, Turner R, Holman R. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
27. Yoshida Y, Hagura R, Hara Y, Sugasawa G, Akanuma Y. Risk factors for the development of diabetic retinopathy in Japanese type 2 diabetic patients. Diab Res and Clin Pract 2001; 51: 195-203.
28. Royal College of Physicians of Edinburgh Diabetes Register Group. Near-normal urinary albumin concentrations predict progression to diabetic nephropathy in type 1 diabetes mellitus. Diabetic Medicine 2000; 17: 782-791.
29. Wolffenbuttel B, Sels J, Rondas-Colbers G, Menheere P. Prognostic factors for successful insulin therapy in subjects with type 2 diabetes. Neth J Med 1999; 54: 63-9.
30. Van Pelt R, Gozansky W, Schwartz R, Kohrt W. Intravenous estrogens increase insulin clearance and action in postmenopausal women. Am J Physiol Endocrinol Metab 2003; 285: E311-E317.